Medpage Today on MSN5d
FDA Rejects Full Approval of Liver Disease DrugThe FDA in 2016 granted accelerated approval to the FXR agonist as a second-line treatment for adults with PBC, either in ...
Senescence, in which cells become tired and stop working effectively, is a common effect of ageing, but can also be triggered ...
A two-year liver health project is underway across the Humber region, aiming to enhance patient care, reduce emergency ...
On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing ...
The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, ...
Obesity, alcohol use and other factors are driving up rates of fatty liver disease among American adults, new research warns.
Liver disease, which is treatable when discovered early, often goes undetected until late stages, but a new study revealed that an algorithm fueled by artificial intelligence can accurately detect ...
As the prevalence of obesity, alcohol use, and liver disease increases, physicians should take note of patients' lifestyle ...
“With a better understanding of risk, clinicians can prioritize their approach to treatment and prevention of metabolic ...
Medpage Today on MSN2d
Primary Biliary Cholangitis Incidence and Prevalence GrowingPrimary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...
GlobalData on MSN3d
Intercept loses Ocaliva FDA full approval bid in rare liver diseaseIntercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback